Completed PHASE1 INTERVENTIONAL 2-arm NCT01378312

A Study to Evaluate Safety and Immunogenicity of AERAS-402

A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-402 When Administered to HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection

Sponsor: Aeras

Conditions Tuberculosis

Interventions AERAS 402 Placebo

Updated 5 times since 2017 Last updated: Mar 14, 2014 Started: Feb 28, 2011 Primary completion: Oct 31, 2011 Completion: Mar 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Tuberculosis, this trial is completed. The trial is conducted by Aeras and has accumulated 5 data snapshots since 2011. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Feb 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aeras

Data source: Aeras

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bangalore, India